Esophageal Cancer Clinical Trial
Official title:
Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer: a Randomized Clinical Trial
The purpose of this study is to determine the feasibility of early oral food intake postoperatively in patients with thoracolaparoscopic esophagectomy. More and more evidence confirmed the role of early early enteral nutrition (NE) after esophagectomy in patients with esophageal cancer. Although enteral catheter feeding has been shown to be beneficial in patients with esophagectomy, the preference for this modality also rests on the traditional but undocumented reluctance to allow food at will. These assumed hazards of allowing normal food in the immediate postoperative period have not been scientifically tested and should be viewed against both the benefits and side effects of any artificial feeding modality. Whether early oral feeding after esophagectomy affects the incidence of life-threatening surgical complications, shortens the recovery time of bowel function and the postoperative hospital stay, improves postoperative quality of life in comparison with artificial feeding modality remains unclear. The investigators compared a routine of allowing liquid food at will from the first day after surgery with a routine of nil-by-mouth and enteral nutrition for the first 7 postoperative days. The main endpoint is the incidence rate of complications.
The literature concludes that patients should be allowed food without delay (at will) after
colorectal surgery and that the customary withholding of oral intake (nil-by-mouth) for the
first postoperative days is unnecessary. Robust data also suggest that the investigators
should avoid the nil-by-mouth regimen after major gynecologic, urologic, and vascular
surgery. The safety of early oral feeding after esophagectomy has not been investigated
previously.In 2008, the results of a randomized multicenter clinical trial investigating
whether a routine of allowing normal food at will immediately increases morbidity after
major upper gastrointestinal surgery showed that allowing patients to eat normal food at
will from the first day after major upper gastrointestinal surgery does not increase
morbidity compared with traditional care with nil-by-mouth and enteral feeding. The assumed
hazards of allowing oral food intake in the immediate postoperative period in patients with
esophagectomy have not been scientifically tested and should be viewed against both the
benefits and side effects of any artificial feeding modality.
This is a randomized study investigating the role of early oral feeding in patients with
esophagectomy.In the early oral feeding group nasogastric tube is not placed routinely and
patients are encouraged to intake liquid food on postoperative day 1 (POD1). In delayed oral
feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20
mL/h until the morning of POD 1. Nutrition was then commenced at 20 mL/h. The rate was
increased by 20 mL/h each day if tolerated, up to 80 mL/h. Esophagography is performed on
postoperative day 7. Sip of water were allowed after confirming the absence of anastomotic
leakage, and a full liquid diet was implemented on the following day and enteral infusion
halted. The complications defined in previous study and bowel function and recovery were
recorded carefully. The primary end point of this study is the postoperative complications
and the secondary end points are quality of life,bowel function recovery time and length of
postoperative stay between the two groups. The investigators estimated the minimum rate of
patients with complications in control group population at 23%. An increase of this to 36%
was considered clinically important. Detecting a difference of this magnitude or greater at
a level of statistical significance of 0.05 and a power of 0.90 with a one-tailed test of
proportions required a total of 130 patients in each group.Considering the rate of drop-out
a total of 280 patients will be enrolled in this study.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |